Suggestions
BJ Sullivan, PhD
Chief Strategy Officer, BioAge Labs
Dr. BJ Sullivan is a highly accomplished professional with a diverse background in molecular biology, pharmacology, and strategy.
He holds a Ph.D. in Molecular & Medical Pharmacology from the prestigious David Geffen School of Medicine at UCLA, where he honed his expertise in the field.
His academic journey also includes an AB, cum laude, in Molecular Biology, Global Health & Health Policy from Princeton University, and he was recognized as Valedictorian at St. Albans School in Washington, D.C.
Dr. Sullivan has held significant roles in various organizations, including BioAge Labs and L.E.K. Consulting.
At BioAge Labs, he showcased his leadership skills as the former Chief Strategy Officer, VP of Strategy & Business Operations, and Chief of Staff.
Prior to his time at BioAge Labs, he made valuable contributions as a Manager, Senior Consultant, Consultant, and Life Sciences Specialist at L.E.K. Consulting.
With a rich academic and professional background, Dr. BJ Sullivan is a versatile expert in molecular biology, pharmacology, and strategic management.
His impressive career progression and experience in diverse roles highlight his adaptability and proficiency in the field of life sciences and consulting.
Highlights
Excited to announce the closing of our $170M Series D financing to accelerate development of obesity and metabolic disease therapeutics. The round was led by Sofinnova Investments with a sterling syndicate of new investors, including Lilly and Amgen.
We are developing our lead program, azelaprag, as an oral therapy for obesity. It has the potential to 1) increase overall weight loss in combination with an incretin, and 2) improve the quality of weight loss, optimizing the balance of lean and fat mass.
We plan to initiate a Ph2 trial of azelaprag co-administered with Lilly's Zepbound in mid-2024.
So excited to announce that we are teaming up with Lilly for a Phase 2 obesity trial combining our lead program, BGE-105 / azelaprag, with their blockbuster GLP-1 / GIP agonist, tirzepatide.
Azelaprag has the potential to achieve best-in-class weight loss in a fully oral incretin combination - the future of obesity treatment.
